CancerDrs

Head and Neck Cancer clinical trials in California

95 actively recruiting head and neck cancer trials at 54 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in California:
  • AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
  • Kaiser Permanente Dublin — Dublin, California
  • Kaiser Permanente-Fremont — Fremont, California
  • Kaiser Permanente Fresno Orchard Plaza — Fresno, California
  • Los Angeles General Medical Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in California:
  • Fremont - Rideout Cancer Center — Marysville, California
  • VA Palo Alto Health Care System — Palo Alto, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Stanford Cancer Institute Palo Alto — Palo Alto, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
  • UC San Diego Medical Center - Hillcrest — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a …

Sponsor: NRG Oncology
NCT ID: NCT07441681
Sites in California:
  • Tower Cancer Research Foundation — Beverly Hills, California
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
  • Cedars-Sinai Medical Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…

Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Sites in California:
  • Site #0107 — La Jolla, California
  • Site #0106 — Los Angeles, California
  • Site#0144 — Sacramento, California
  • Site #0130 — San Francisco, California
  • Site #0150 — Stanford, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in California:
  • Providence St Jude Medical Center — Fullerton, California
  • Scripps Health — La Jolla, California
  • Valkyrie Clinical Trials — Los Angeles, California
  • University of California, Los Angeles UCLA — Los Angeles, California
  • Valkyrie Clinical Trials Murrieta — Murrieta, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…

Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • University of California Los Angeles Westwood Cancer Center — Los Angeles, California
  • Stanford Medicine - Cancer Center — Palo Alto, California
  • Moores Cancer Center — San Diego, California
  • UCSF Head and Neck Surgery Cancer Program — San Francisco, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in California:
  • GSK Investigational Site — Los Angeles, California
  • GSK Investigational Site — Solvang, California
  • GSK Investigational Site — Stockton, California
  • GSK Investigational Site — Torrance, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in California:
  • City of Hope Corona — Corona, California
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • City of Hope at Irvine Lennar — Irvine, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in California:
  • University of California Los Angeles — Los Angeles, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn ab…

Sponsor: Rakuten Medical, Inc.
NCT ID: NCT06699212
Sites in California:
  • City of Hope — Duarte, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…

Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in California:
  • City of Hope National Medical Center — Duarte, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Kaiser Permanente-Bellflower — Bellflower, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in California:
  • Keck Medicine of USC Buena Park — Buena Park, California
  • UC San Diego Health System - Encinitas — Encinitas, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Los Angeles General Medical Center — Los Angeles, California
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where …

Sponsor: NRG Oncology
NCT ID: NCT05408845
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • Kaiser Permanente Dublin — Dublin, California
  • Kaiser Permanente-Fremont — Fremont, California
  • Kaiser Permanente Fresno Orchard Plaza — Fresno, California
  • Kaiser Permanente-Fresno — Fresno, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in California:
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
  • Stanford Cancer Institute Palo Alto — Palo Alto, California
  • Sutter Medical Center Sacramento — Sacramento, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in California:
  • Kaiser Permanente Dublin — Dublin, California
  • Kaiser Permanente-Fremont — Fremont, California
  • Kaiser Permanente Fresno Orchard Plaza — Fresno, California
  • Kaiser Permanente-Fresno — Fresno, California
  • Keck Medicine of USC Koreatown — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in California:
  • Kaiser Permanente Downey Medical Center — Downey, California
  • Loma Linda University Medical Center — Loma Linda, California
  • Children's Hospital Los Angeles — Los Angeles, California
  • Valley Children's Hospital — Madera, California
  • UCSF Benioff Children's Hospital Oakland — Oakland, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in California:
  • Local Institution - 2129 — Duarte, California
  • Local Institution - 2120 — Glendale, California
  • Local Institution - 2136 — La Jolla, California
  • Local Institution - 2114 — La Jolla, California
  • Local Institution - 2121 — Long Beach, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California:
  • University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
  • University of San Diego Moores Cancer Center — La Jolla, California
  • UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in California:
  • City of Hope — Duarte, California
  • Los Angeles Cancer Network — Glendale, California
  • California Research Institute — Los Angeles, California
  • Valkyrie Clinical Trials — Los Angeles, California
  • Valkyrie Clinical Trials — Murrieta, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in California:
  • Avenzo Therapeutics Recruiting Site — Los Angeles, California
  • Avenzo Therapeutics Recruiting Site — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California:
  • Valkyrie Clinical Trials — Los Angeles, California
  • Los Angeles Cancer Network — Los Angeles, California
  • Pih Health Hematology Medical Oncology — Whittier, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in California:
  • City of Hope — Duarte, California
  • City of Hope, Irvine — Irvine, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in California:
  • VA Greater Los Angeles Healthcare System — Los Angeles, California
  • UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
View on ClinicalTrials.gov →

Showing 25 of 95 trials with sites in California. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12